# Cagrilintide (and CagriSema)

Source: https://aminodesk.com/library/cagrilintide
Publisher: Amino Desk
Updated: 2026-11-17
Clinical review: pending

Cagrilintide is an experimental weekly injection from Novo Nordisk that mimics amylin, a hormone released with insulin that helps signal fullness. Combined with semaglutide it is called CagriSema, which is under FDA review. Neither is approved.

- **Legal lane:** investigational. Not approved; cannot be used in compounding.
- **Evidence grade:** B
- **Form:** weekly injection under the skin
- **US status:** CagriSema application filed December 2025; decision expected late 2026

## What it is

Cagrilintide is a long-acting version of amylin. It works on different receptors from GLP-1 drugs, so the idea behind CagriSema is to add two appetite signals together. The first drugs of each kind, pramlintide and exenatide, were both approved in 2005.

## What the evidence shows

- **REDEFINE 1** (New England Journal of Medicine, 2025): 3,417 adults with obesity or overweight and no diabetes, treated for 68 weeks. CagriSema produced an average weight loss of 20.4% counting everyone assigned to it, and 22.7% among people who stayed on treatment. The trial also had cagrilintide-alone and semaglutide-alone arms.
- **REDEFINE 2** (same journal, 2025): 1,206 adults with type 2 diabetes. Weight loss was smaller, about 13.7%, as is usual in people with diabetes.

The grade is B rather than A because the strong evidence is for the combination. Vials sold online are cagrilintide alone, which has much less data, and nothing is known about their content.

## Dosing used in the trials

There is no approved dose. In REDEFINE 1 the target was 2.4 mg of cagrilintide plus 2.4 mg of semaglutide once a week, reached by gradual increases; about 75% of participants reached the full dose. Investigators could keep people on a lower dose if needed.

## Legal status

Novo Nordisk filed for FDA approval of CagriSema in December 2025 and has said it expects a decision in the fourth quarter of 2026. The FDA states that cagrilintide cannot be used in compounding under federal law, so "compounded CagriSema" and research vials are unapproved and unverified.

## Common questions

### Is cagrilintide FDA-approved?

No. Novo Nordisk filed for approval of CagriSema, the combination with semaglutide, in December 2025 and has said it expects a decision in the fourth quarter of 2026.

### How much weight did people lose on CagriSema?

In REDEFINE 1, average weight loss over 68 weeks was 20.4% counting everyone assigned to it, and 22.7% among people who stayed on treatment. That evidence is for the combination, not cagrilintide alone.

### Can cagrilintide be compounded?

No. The FDA states that cagrilintide cannot be used in compounding under federal law.

Added in the latest update. These answers summarize the sections above; sources are listed below.

## Sources

- [Garvey et al. 2025: REDEFINE 1, New England Journal of Medicine](https://www.nejm.org/doi/full/10.1056/NEJMoa2502081)
- [Davies et al. 2025: REDEFINE 2, New England Journal of Medicine](https://www.nejm.org/doi/full/10.1056/NEJMoa2502082)
- [FDA: Concerns with unapproved GLP-1 drugs used for weight loss](https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss)
- [Novo Nordisk: FDA application for CagriSema, December 2025](https://www.prnewswire.com/news-releases/novo-nordisk-files-for-fda-approval-of-cagrisema-the-first-once-weekly-combination-of-glp1-and-amylin-analogues-for-weight-management-302645862.html)

---
Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL.
